解读新药品管理法：持有人责任强化，市场独占期制度性落地

Core Viewpoint - The National Medical Products Administration (NMPA) is actively promoting the formulation of the "Implementation Measures for the Protection of Drug Trial Data," responding to the needs of the innovative drug industry and enhancing the regulatory framework to support drug development in China [1] Group 1: Drug Trial Data Protection - The revised "Regulations" expand the scope of drug trial data protection to include drugs with new chemical entities, providing a protection period of up to 6 years for undisclosed trial data [2] - The NMPA has previously solicited public opinions on the "Implementation Measures for the Protection of Drug Trial Data," indicating a move towards more concrete regulations [2] Group 2: Market Exclusivity Period - The new "Regulations" establish a market exclusivity period for innovative drugs, which had previously been discussed only in draft forms [3] - For new pediatric drugs and rare disease treatments, the exclusivity period can be up to 2 years and 7 years respectively, incentivizing the development of these critical medications [4] Group 3: Conditional Release of Drug Contracted Segment Production - The "Regulations" clarify conditions under which contracted segment production can be permitted, particularly for innovative drugs with special production requirements [6][7] - The segment production model has shown potential in reducing costs while maintaining efficacy, as evidenced by the successful registration of a rare disease treatment [6] Group 4: Strengthened Oversight of Imported Drug Batches - The "Regulations" enhance the oversight of commercial-scale batches of drugs approved for import before market approval, allowing for their sale under strict compliance with Good Manufacturing Practice (GMP) [8] - This approach aims to balance drug safety with the urgent clinical needs of patients, particularly for new drugs and treatments for rare diseases [8]